3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 3
2
Phase 2/3
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
30
Tumor-Agnostic
2
CNS
1
Conditions
Neoplasms
1
Neoplasm Metastasis
1
Carcinoma
1
Interventions
Carboplatin
8
Paclitaxel
7
Fluorouracil
7
Cisplatin
7
atezolizumab
5
Trastuzumab
5
Pemetrexed
5
Oxaliplatin
5
Leucovorin
5
Bevacizumab
5
pembrolizumab
4
Gemcitabine
4
Capecitabine
4
Albumin-Bound Paclitaxel
4
Surveys and Questionnaires
3
Observation
3
Leuprolide
3
Irinotecan
3
Glutamine
3
Drug Therapy
3
Docetaxel
3
Dexamethasone
3
130-nm albumin-bound paclitaxel
3
trifluridine tipiracil drug combination
2
regorafenib
2
osimertinib
2
enzalutamide
2
Surgical Procedures, Operative
2
Standard of Care
2
Sorafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
osimertinib
×
Tumor-Agnostic
×
Clear all
NCT05261399
2026-04-06
SAFFRON
AstraZeneca
Phase 3
Active not recruiting
345 enrolled
NCT05629234
2026-04-06
ROSY-T
AstraZeneca
Phase 3
Active not recruiting
37 enrolled